Quantification of biological variation in blood-based therapy - a summary of a meta-analysis to inform manufacturing in the clinic-Reference-Cited by-同舟云学术

Quantification of biological variation in blood-based therapy - a summary of a meta-analysis to inform manufacturing in the clinic

Published:2015-07-14 Issue:4 Volume:109 Page:394-402
ISSN:0042-9007
Container-title:Vox Sanguinis
language:en
Short-container-title:Vox Sang

Author:

Thurman-Newell J. A.¹,Petzing J. N.¹,Williams D. J.¹

Affiliation:

1. Healthcare Engineering Group; Centre for Biological Engineering; Loughborough University; Loughborough UK

Funder

Engineering and Physical Sciences Research Council

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/vox.12288/fullpdf

Reference30 articles.

1. British Standards Institute PAS 83:2012. Developing human cells for clinical applications in the European Union and the United States of America 2012

2. The effect of total nucleated and CD34+ cell dose on outcome after allogeneic hematopoietic stem cell transplantation;Remberger;Biol Blood Marrow Transplant,2015

3. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?;Jillella;Stem Cells Dev,2004

4. Hematopoietic stem cells in research and clinical applications: the ‘CD34 issue’;Ivanovic;World J Stem Cells,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Protocol Impact on Subjectivity Uncertainty When Analyzing Peripheral Blood Mononuclear Cell Flow Cytometry Data Files;Methods and Protocols;2021-03-30

2. Understanding the contribution of operator measurement variability within Flow Cytometry data analysis for Quality Control of Cell and Gene Therapy manufacturing;Measurement;2020-01

3. Establishing the variation of blood metrics within UK Biobank to inform cell therapy manufacturing processes;Regenerative Medicine;2019-11

4. Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop;Regenerative Medicine;2018-12

5. Scanning the horizon for high value-add manufacturing science: Accelerating manufacturing readiness for the next generation of disruptive, high-value curative cell therapeutics;Cytotherapy;2018-05